World journal of gastroenterology : WJG
-
World J. Gastroenterol. · Aug 2014
Randomized Controlled Trial Multicenter StudyFurazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection.
To evaluate the efficacy of furazolidone-based triple and quadruple therapy in eradicating Helicobacter pylori (H. pylori) in a multi-center randomized controlled trial. ⋯ Both 7- and 10-d quadruple furazolidone-based therapies achieve satisfactory H. pylori eradication rates.
-
World J. Gastroenterol. · Aug 2014
Hospitalization for variceal hemorrhage in an era with more prevalent cirrhosis.
To examine hospitalization rates for variceal hemorrhage and relation to cause of cirrhosis during an era of increased cirrhosis prevalence. ⋯ Hospitalizations for variceal hemorrhage have decreased, most notably in patients with non-alcoholic cirrhosis, and this may reflect broader use of strategies to prevent bleeding.
-
World J. Gastroenterol. · Aug 2014
Observational StudyClinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.
To evaluate the efficacy and safety of tolvaptan to treat refractory ascites in decompensated liver cirrhosis patients with or without further complications, such as hepatorenal syndrome and/or hepatocellular carcinoma. ⋯ Tolvaptan is a promising aquaretic for the treatment of refractory ascites in patients with decompensated liver cirrhosis.
-
World J. Gastroenterol. · Aug 2014
Glutamine prevents oxidative stress in a model of mesenteric ischemia and reperfusion.
To evaluate preventative effects of glutamine in an animal model of gut ischemia/reperfusion (I/R). ⋯ These results demonstrate that pretreatment with glutamine prevents mucosal injury and improves gut and lung recovery after I/R injury in rats.
-
World J. Gastroenterol. · Aug 2014
Comparative StudyLiving donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation.
To compare the recurrence-free survival (RFS) and overall survival (OS) of hepatitis B virus (HBV)-positive hepatocellular carcinoma (HCC) after living donor liver transplantation (LDLT) and deceased donor liver transplantation (DDLT). ⋯ The outcomes of LDLT for HCC are not worse compared to the outcomes of DDLT. LDLT does not increase tumor recurrence of HCC compared to DDLT.